Ceylad Gets FDA Nod to Begin Phase I Study on CAR T Candidate

Shares of Celyad Oncology SA (CYAD) went up about 10.8% after it announced that the FDA cleared the investigational new drug (IND) application for its short hairpin RNA (shRNA)-based allogeneic candidate, CYAD-211, for the treatment of relapsed/refractory multiple myeloma (r/r MM). The phase I study for the candidate is expected to begin by the end of 2020. CYAD-211 targets B-cell maturation antigen (BCMA) protein/antigen and represents the company’s lead off-the-shelf product candidate based on differentiated non-gene edited allogeneic technology

However, shares of the company have gained 5.1% compared with the industry’s growth of 6.4%.

The company is developing several allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors.

There are a number of big pharmaceutical companies that are also developing CAR T Therapies. One such company is Gilead Sciences Inc. GILD. Gilead is seeking approval for its CAR T therapy candidate, KTE-X19, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

Novartis’ NVS CAR T therapy drug, Kymriah, is also approved in the United States for B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.


Celyad SA Price


Celyad SA Price

Celyad SA price | Celyad SA Quote

Zacks Rank and Another Stock to Consider

Celyad currently carries a Zacks Rank #4 (Sell). A top-ranked stock in the biotech sector is Emergent Biosolutions Inc. EBS, carrying a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Emergent’s earnings per share estimates have increased from $3.18 to $4.03 for 2020 and from $3.32 to $4.31 for 2021 in the past 60 days.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Novartis AG (NVS): Free Stock Analysis Report
Emergent Biosolutions Inc. (EBS): Free Stock Analysis Report
Celyad SA (CYAD): Free Stock Analysis Report
To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.